PredictImmune

The company's business was centered on developing and marketing prognostic tests to guide treatment for complex, immune-mediated inflammatory diseases. Its clients were primarily clinicians, specifically gastroenterologists, who treat patients with conditions like Inflammatory Bowel Disease (IBD). PredictImmune's revenue model was based on the sale of these diagnostic tests, which aimed to provide significant clinical and economic benefits by personalizing treatment from the point of diagnosis. The company also pursued partnerships with pharmaceutical companies to use its tests for stratifying patients in clinical trials for new drugs.

PredictImmune's flagship product was PredictSURE IBD™, a prognostic test for patients with Crohn's disease and ulcerative colitis. This blood test analyzed specific genetic biomarkers to forecast the long-term course of the disease. Its main benefit was enabling clinicians to differentiate between patients likely to have a mild disease course and those at risk of severe, relapsing illness. This insight allows for the immediate selection of the most appropriate treatment pathway, avoiding the under-treatment of high-risk patients and the over-treatment of those with a milder prognosis. The test received a CE mark in December 2018, permitting its sale across the UK and Europe, and the company later partnered with KSL Biomedical to commercialize it in North America. However, according to PitchBook, the company is now out of business as of early 2024.